10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP increased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 240.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,236,200 shares of the company's stock after buying an additional 873,200 shares during the period. Two Sigma Advisers LP owned about 1.02% of 10x Genomics worth $17,752,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TXG. Signaturefd LLC grew its stake in shares of 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after acquiring an additional 1,452 shares in the last quarter. Blue Trust Inc. grew its stake in 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after purchasing an additional 1,299 shares in the last quarter. Sound Income Strategies LLC grew its stake in 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after purchasing an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in 10x Genomics during the 4th quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. raised its position in shares of 10x Genomics by 817.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after purchasing an additional 4,324 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 5,092 shares of the business's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares in the company, valued at approximately $9,735,865.74. The trade was a 0.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares in the company, valued at $3,712,036.68. This trade represents a 1.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.39% of the company's stock.

Wall Street Analyst Weigh In

TXG has been the subject of a number of recent analyst reports. UBS Group decreased their price target on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Citigroup cut their target price on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Canaccord Genuity Group decreased their price target on 10x Genomics from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Stephens restated an "overweight" rating and set a $14.00 price objective on shares of 10x Genomics in a research note on Thursday, May 15th. Finally, Stifel Nicolaus reduced their target price on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $15.81.

10x Genomics Stock Performance

TXG stock opened at $8.32 on Thursday. 10x Genomics, Inc. has a 1 year low of $6.78 and a 1 year high of $24.76. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -5.47 and a beta of 1.94. The stock's fifty day moving average is $8.68 and its two-hundred day moving average is $12.21.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The firm had revenue of $154.88 million for the quarter, compared to the consensus estimate of $131.91 million. During the same period last year, the firm posted ($0.50) EPS. 10x Genomics's quarterly revenue was down 2.3% compared to the same quarter last year. As a group, analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.